Roche flash­es new 16-week bis­pe­cif­ic AMD da­ta, set­ting eyes on pair of PhI­II tri­als

While Roche awaits re­sults from a pair of large Phase III tri­als, the Swiss phar­ma is tout­ing an­oth­er round of da­ta from a small­er study on its wet mac­u­lar de­gen­er­a­tion (nAMD) bis­pe­cif­ic an­ti­body, faricimab.

Al­though new, the da­ta large­ly con­firm re­sults Roche and its Genen­tech sub­sidiary flashed from the Phase II study two years ago, with both rounds sug­gest­ing that the ex­per­i­men­tal drug could be giv­en once every 12 or 16 weeks, as op­posed to the 4 weeks re­quired for their long-run­ning AMD block­buster Lu­cen­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER